NEET proteins as novel drug targets for mitochondrial dysfunction

Henri Baptiste Marjault, Ke Zuo, Ron Mittler, Paolo Carloni, Rachel Nechushtai

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

5 Scopus citations

Abstract

NEET proteins belong to a newly discovered class of iron-sulfur proteins that harbor a unique labile [2Fe-2S] cluster and is thought to play a major role in preventing mitochondrial dysfunction. Mitochondrial dysfunction is associated with many human pathologies including diabetes, inflammation, neurodegeneration, and cancer. The degree of NEET [2Fe-2S] cluster stability was recently shown to affect mitochondrial function. Nevertheless, only a few compounds have thus far been discovered or designed as NEET ligands that control NEET [2Fe-2S] stability. This chapter summarizes the role of NEET proteins in different diseases and highlights the need to develop additional NEET ligands with a high therapeutic potential.

Original languageAmerican English
Title of host publicationClinical Bioenergetics
Subtitle of host publicationFrom Pathophysiology to Clinical Translation
PublisherElsevier
Pages477-488
Number of pages12
ISBN (Electronic)9780128196212
DOIs
StatePublished - 1 Jan 2020

Bibliographical note

Publisher Copyright:
© 2021 Elsevier Inc. All rights reserved.

Keywords

  • Cluster lability
  • Drug design
  • Iron-sulfur proteins
  • Mitochondrial dysfunction
  • NEET proteins

Fingerprint

Dive into the research topics of 'NEET proteins as novel drug targets for mitochondrial dysfunction'. Together they form a unique fingerprint.

Cite this